Research programme: chimeric antigen T-cell therapies - bluebird bioAlternative Names: CAR T-cell therapy - bluebird bio
Latest Information Update: 14 Jul 2016
At a glance
- Originator bluebird bio
- Class CAR-T cell therapies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 15 Mar 2016 Biomarkers information updated